Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.

This study has been terminated.
(Competing study was started.)
Sponsor:
Information provided by (Responsible Party):
Masonic Cancer Center, University of Minnesota
ClinicalTrials.gov Identifier:
NCT00354172
First received: July 19, 2006
Last updated: November 6, 2012
Last verified: November 2012
  Purpose

RATIONALE: Giving chemotherapy, natural killer cells, aldesleukin, and total-body irradiation before a donor umbilical cord blood stem cell transplant helps stop the growth of abnormal cells and cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclosporine, mycophenolate mofetil, and methylprednisolone before and after transplant may stop this from happening.

PURPOSE: This clinical trial is studying how well giving fludarabine and cyclophosphamide together with total-body irradiation followed by donor umbilical cord blood natural killer cells, aldesleukin, and umbilical cord blood transplant works in treating patients with refractory hematologic cancer or other diseases.


Condition Intervention Phase
Leukemia
Myelodysplastic Syndromes
Biological: aldesleukin
Biological: filgrastim
Biological: natural killer cell (NK) therapy
Drug: cyclophosphamide
Drug: cyclosporine
Drug: fludarabine phosphate
Drug: methylprednisolone
Drug: mycophenolate mofetil
Procedure: Umbilical Cord Blood Transplantation (UCBT)
Radiation: Total body irradiation (TBI)
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Transplantation of Umbilical Cord Blood for Myeloid Leukemia Patients Not in CR With Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen and UCB NK Cells

Resource links provided by NLM:


Further study details as provided by Masonic Cancer Center, University of Minnesota:

Primary Outcome Measures:
  • Number of Participants (Patients) Who Were Disease-free and Alive at 6 Months [ Time Frame: 6 Months Post Transplant ] [ Designated as safety issue: No ]
    Number of patients who were alive and free of disease (malignancy) at 6 months after transplant.


Secondary Outcome Measures:
  • Number of Participants (Patients) Who Were Disease-free and Alive at 12 Months [ Time Frame: 12 Months Post transplant ] [ Designated as safety issue: No ]
    Number of patients who were alive and free of disease (malignancy) at 12 months after transplant.

  • Number of Patients Who Were Disease-free and Alive at 24 Months [ Time Frame: 24 Months Post transplant ] [ Designated as safety issue: No ]
    Number of patients who were alive and free of disease (malignancy) at 24 months after transplant.

  • Number of Participants (Patients) Who Died Due to Transplant. [ Time Frame: 6 Months Post Transplant ] [ Designated as safety issue: Yes ]
    Patients who had transplant-related mortality (TRM). TRM = adverse event(s) that occur(s) after the patient has received a transplant, the principal investigator decides it is related to the procedure and the patient dies within 6 months.

  • Number of Participants (Patients) Who Attained Neutrophil Engraftment [ Time Frame: Day 42 Post Transplant ] [ Designated as safety issue: No ]

    Defined as absolute neutrophils (ANC) > 5 x 10^8/Liter for 3 consecutive days.

    ANC is the real number of white blood cells (WBCs) that are neutrophils. The absolute neutrophil count is commonly called the ANC. The ANC is not measured directly. It is derived by multiplying the WBC count times the percent of neutrophils in the differential WBC count. The percent of neutrophils consists of the segmented (fully mature) neutrophils) + the bands (almost mature neutrophils). The normal range for the ANC = 1.5 to 8.0 (1,500 to 8,000/mm3).


  • Number of Participants (Patients) Who Attained Platelet Engraftment [ Time Frame: 1 Year Post Transplant ] [ Designated as safety issue: No ]
    Platelet engraftment is defined as platelet counts > 50 x 10^9/Liter for 3 consecutive days.

  • Number of Participants (Patients) With Acute Graft-versus-host Disease (GVHD) Grade II-IV [ Time Frame: Day 100 Post Transplant ] [ Designated as safety issue: No ]
    Graft-versus-host disease (GVHD) is a common complication of transplantation in which functional immune cells in the transplanted marrow recognize the recipient as foreign and mount an immunologic attack. The acute or fulminant form of the disease (aGVHD) is normally observed within the first 100 days post-transplant, and is a major challenge to transplants owing to associated morbidity and mortality. Acute GVHD is staged as follows: overall grade (skin-liver-gut) with each organ staged individually from a low of I to a high of IV. Patients with grade IV GVHD usually have a poor prognosis.

  • Number of Participants (Patients) With Acute Graft-versus-Host Disease at Grade III-IV [ Time Frame: Day 100 post transplant ] [ Designated as safety issue: No ]
    Graft-versus-host disease (GVHD) is a common complication of transplantation in which functional immune cells in the transplanted marrow recognize the recipient as foreign and mount an immunologic attack. The acute or fulminant form of the disease (aGVHD) is normally observed within the first 100 days post-transplant, and is a major challenge to transplants owing to associated morbidity and mortality. Acute GVHD is staged as follows: overall grade (skin-liver-gut) with each organ staged individually from a low of I to a high of IV. Patients with grade IV GVHD usually have a poor prognosis.

  • Number of Participants (Patients) With Chronic Graft-Versus-Host Disease [ Time Frame: Day 100 through 1 Year Post Transplant ] [ Designated as safety issue: No ]
    The chronic form of graft-versus-host-disease (cGVHD) normally occurs after 100 days. The appearance of moderate to severe cases of cGVHD adversely influences long-term survival.

  • Number of Participants (Patients) Who Died by 12 Months [ Time Frame: 1 year Post Transplant ] [ Designated as safety issue: No ]
    Number of patients who died after receiving treatment within 12 months post transplant.

  • Number of Participants (Patients) Who Died by 24 Months [ Time Frame: 2 years post-transplant ] [ Designated as safety issue: No ]
    Number of patients who died after receiving treatment within 24 months post transplant.

  • Number of Participants (Patients) Who Experienced Relapse by 12 Months [ Time Frame: 1 Year Post Transplant ] [ Designated as safety issue: No ]
    Number of patients who experienced recurrence or progression of disease from the time of transplant.

  • Number of Participants (Patients) Who Experienced Relapse by 24 Months [ Time Frame: 2 Years Post transplant ] [ Designated as safety issue: No ]
    Number of patients who experienced recurrence or progression of disease from the time of transplant.

  • Number of Participants (Patients) With Successful Natural Killer Cell Expansion [ Time Frame: 10-13 Days Post Infusion ] [ Designated as safety issue: No ]
    Defined by an absolute circulating donor-derived natural killer cell count of >100 cells/microliter 10-13 days after infusion with <5% donor T and B cells in the mononuclear population

  • Chimerism After Double Umbilical Cord Blood Transplant (UCBT) [ Time Frame: Day 21, Day 100, 6 Months ] [ Designated as safety issue: No ]
    Calculation of Median (range) of percentage of donor cells engrafted (present) in the recipient (patient).


Enrollment: 16
Study Start Date: February 2006
Study Completion Date: August 2008
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treated Patients
All patients receiving treatment with chemotherapy and radiation, along with natural killer cells, aldesleukin and umbilical cord blood transplant.
Biological: aldesleukin
10 Million units subcutaneous every other day on days -13 (after Natural killer cell graft), -11, -9, -7, -5, -3) If < 45 kilograms (Kg) - interleukin (IL)-2 at 5 MU/m2
Other Names:
  • IL-2
  • interleukin-2
Biological: filgrastim
All patients will receive filgrastim (same as granulocyte-colony stimulating factor or G-CSF) 5 mcg/kg/day intravenous (IV) (dose rounded to vial size) based on the actual body weight beginning on day +1 after umbilical cord blood (UCB) infusion. Granulocyte Colony Stimulating Factor (G-CSF) will be administered daily until the absolute neutrophil count (ANC) exceeds 2.5 x 10^9/L for three consecutive days and then discontinued. If the ANC decreases to <1.0 x 10^9/L, G-CSF will be reinstituted.
Other Name: granulocyte colony-stimulating factor (G-CSF)
Biological: natural killer cell (NK) therapy
All CD3 depleted cells will be given (less those required for product monitoring). The minimum size of a starting NK cell unit will be 700 million mononuclear cells before processing. NK cells (CD56+) and NK cell precursors (CD34+/CD7-, CD34+/CD7+, CD34-/CD7+) will be monitored and reported but will not serve as lot release.
Other Name: NK cells
Drug: cyclophosphamide
Cyclophosphamide to be administered with high volume fluid flush and mesna on days-18 and -17 after fludarabine. Cyclophosphamide 60 mg/kg/day intravenously (IV) x 2 days, total dose 120 mg/m2 (days -18 and -17)
Other Name: Cytoxan
Drug: cyclosporine
Patients will receive cyclosporine (CSA) therapy beginning on day -1 maintaining a level of >200 ng/mL. For adults the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours. For children <40 kg the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours.
Other Name: cyclosporin
Drug: fludarabine phosphate
Fludarabine 25 mg/m2/day intravenously (IV) x 3 days, total dose 75 mg/m2 (days -18 to -16)
Other Name: Fludara
Drug: methylprednisolone

This modification will be enacted based on the engraftment stopping rule on all subsequent patients to stop natural killer (NK) cell reaction.

Methylprednisolone bolus 1000 mg intravenously (IV) will be administered day -1 and day 0 (before umbilical cord blood transplant) to suppress natural killer (NK) cell activity before transplant. Starting cyclosporin and mycophenolate mofetil (MMF) will also contribute to suppressing residual NK cell activity.

Other Names:
  • Medrol
  • Solu-Medrol
  • Depo-Medrol
  • methylprednisolone sodium succinate
Drug: mycophenolate mofetil

All patients will begin mycophenolate mofetil (MMF) on day -1. Patients

≥ 45 kilograms will receive MMF at the dose of 3 grams/day divided into 2 or 3 doses. Pediatric patient (<45 kilograms) will receive MMF at the dose of 15 mg/kg. Use intravenous (IV) route between days -1 and +5, then, if tolerated, may change to by mouth (PO) between days +6 and +30.

Stop MMF at day +30 or 7 days after engraftment, whichever day is later, if no acute Graft Versus Host Disease. (Definition of engraftment is 1st day of 3 consecutive days of absolute neutrophil count [ANC] > 0.5 x 10^9 /L).

Other Name: mycophenolic acid
Procedure: Umbilical Cord Blood Transplantation (UCBT)
The product is infused via intravenous (IV) drip directly into the central line without a needle, pump or filter.
Other Name: allogeneic transplant
Radiation: Total body irradiation (TBI)

TBI 165 Gray (cGy) will be given twice daily for a total dose of 1320 cGy (days

-16 to -13).

Other Name: radiation

Detailed Description:

OBJECTIVES:

Primary

  • Determine the incidence of 6-month disease free survival. The primary laboratory objective is the measure of in vivo expansion of umbilical cord blood (UCB) derived natural killer cells (NK) after a fully ablative preparative regimen.

Secondary

  • Determine the incidence of transplant-related mortality at 6 months after NK UCB + double UCBT
  • Evaluate the pattern of chimerism after NK UCB + double UCBT
  • Determine the incidence of neutrophil engraftment at day 42 after NK UCB + double umbilical cord blood transplantation (UCBT)
  • Determine the incidence of platelet engraftment at 6 months after NK UCB + double UCBT
  • Determine the incidence of acute graft-versus-host disease (GVHD) grade II-IV and grade III-IV at day 100 after NK UCB + double UCBT
  • Determine the incidence of chronic GVHD at 1 year after NK UCB + double UCBT
  • Determine the disease-free survival at 1 after NK UCB + double UCBT
  • Determine the incidence of relapse at 1 after NK UCB + double UCBT

OUTLINE: This is a single arm, nonrandomized, open-label study.

  • Myeloablative conditioning regimen: Patients receive fludarabine intravenously (IV) over 1 hour on days -18 to -16 and cyclophosphamide intravenously (IV) on days -18 and -17. Patients undergo total-body irradiation twice daily on days -16 to -13.
  • Haploidentical umbilical cord blood (UCB) natural killer (NK) cell therapy and aldesleukin: Patients undergo haploidentical UCB-enriched NK cell (CD3- depleted) infusion on day -13. Patients then receive aldesleukin subcutaneously on days -13, -11, -9, -7, -5, and -3. Some patients may also receive methylprednisolone IV on days -1 and 0.
  • UCB transplantation (UCBT): Patients undergo a single or double UCBT on day 0. Beginning on day 1, patients receive filgrastim (G-CSF) IV once daily until blood counts recover.
  • Graft-vs-host disease (GVHD) prophylaxis: Patients receive cyclosporine IV over 2 hours 2-3 times daily beginning on day -1 and continuing until day 100, followed by a taper until day 180. Patients also receive mycophenolate mofetil IV or orally 2-3 times daily beginning on day -1 and continuing until day 30 (or 7 days after engraftment) in the absence of acute GVHD.
  Eligibility

Ages Eligible for Study:   up to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of 1 of the following:

    • Acute myeloid leukemia with active leukemia (i.e., not in complete remission [CR]), defined by light microscopy (bone marrow) and having failed ≥ 1 round of standard chemotherapy
    • Chronic myelogenous leukemia with myeloid blast crisis not in second chronic phase after ≥ 1 course of standard chemotherapy and imatinib mesylate
    • Myelodysplastic syndromes (MDS) or other myeloproliferative disorders more than 10% blasts after ≥ 1 course of standard chemotherapy
  • Unrelated umbilical cord blood (UCB) donor(s) available - Each unit must be 4-6/6 HLA-A, -B, and -DRB1 matched with the recipient (and to each other if 2 units are utilized) (for UCB graft) AND 3/6 HLA-A, -B, and -DRB1 matched with the recipient (for UCB natural killer [NK] cells)
  • Karnofsky performance status (PS) 80-100% (adult patients) or Lansky PS 50-100% (pediatric patients)
  • Creatinine ≤ 2.0 mg/dL (adult patients) OR creatinine clearance > 40 mL/min (pediatric patients)
  • Bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), Alkaline phosphatase ≤ 5 times upper limit of normal (ULN)
  • Corrected Carbon Monoxide Diffusing Capacity (DLCO) > 50% normal OR oxygen saturation > 92% (in pediatric patients who cannot undergo pulmonary function tests)
  • Left ventricular ejection fraction ≥ 45%

Exclusion Criteria:

  • Pregnant or nursing
  • Positive pregnancy test (Fertile patients must use effective contraception)
  • History of HIV infection
  • Active infection at time of transplantation

    • Active infection with Aspergillus or other mold within the past 120 days
  • Less than 6 months since prior myeloablative transplant (≤ 18 years old)
  • Prior myeloablative allotransplant or autologous transplant (> 18 years old)
  • No prior extensive therapy including > 12 months of any alkylator chemotherapy or > 6 months of alkylator therapy with extensive radiation (e.g., mantle irradiation for Hodgkin's lymphoma)
  • Prior radiation therapy that would make the patient ineligible for total-body irradiation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00354172

Locations
United States, Minnesota
Masonic Cancer Center at University of Minnesota
Minneapolis, Minnesota, United States, 55455
Sponsors and Collaborators
Masonic Cancer Center, University of Minnesota
Investigators
Principal Investigator: Jeffrey Miller, MD Masonic Cancer Center, University of Minnesota
  More Information

No publications provided

Responsible Party: Masonic Cancer Center, University of Minnesota
ClinicalTrials.gov Identifier: NCT00354172     History of Changes
Other Study ID Numbers: UMN-2005LS058, MT2005-18, 0509M73449
Study First Received: July 19, 2006
Results First Received: November 30, 2009
Last Updated: November 6, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Masonic Cancer Center, University of Minnesota:
previously treated myelodysplastic syndromes
secondary myelodysplastic syndromes
childhood myelodysplastic syndromes
adult acute myeloid leukemia with 11q23 (MLL) abnormalities
adult acute myeloid leukemia with inv(16)(p13;q22)
adult acute myeloid leukemia with t(15;17)(q22;q12)
adult acute myeloid leukemia with t(16;16)(p13;q22)
adult acute myeloid leukemia with t(8;21)(q22;q22)
atypical chronic myeloid leukemia
blastic phase chronic myelogenous leukemia
childhood chronic myelogenous leukemia
recurrent adult acute myeloid leukemia
recurrent childhood acute myeloid leukemia
relapsing chronic myelogenous leukemia
secondary acute myeloid leukemia

Additional relevant MeSH terms:
Myelodysplastic Syndromes
Central Nervous System Agents
Leukemia
Leukemia, Myeloid
Preleukemia
Neoplasms by Histologic Type
Neoplasms
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Cyclophosphamide
Cyclosporins
Cyclosporine
Mycophenolate mofetil
Fludarabine monophosphate
Fludarabine
Aldesleukin
Interleukin-2
Methylprednisolone Hemisuccinate
Prednisolone
Mycophenolic Acid
Lenograstim
Vidarabine
Methylprednisolone
Methylprednisolone acetate
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
Immunosuppressive Agents
Immunologic Factors

ClinicalTrials.gov processed this record on July 22, 2014